Shares of Altisource Portfolio Solutions S.A. (ASPS) are down more than 34% in midday trading after the company announced that William C. Erbey, founder, chairman and Altisource’s largest stockholder will resign from several of his corporate posts. Mr. Erbey, who served as Director and Chairman of the company since August 2009, stepped down in connection with the Consent Order entered into by Ocwen Financial Corporation (OCN) with the New York Department of Financial Services.
ASPS shares recently lost $16.25 to $31.29. In the past 52 weeks, shares of Luxembourg-based firm have traded between a low of $30.72 and a high of $164.92. Shares are down 70.18% year-over-year and 70.03% year-to-date.
Advaxis, Inc. (ADXS) is seeing a big move Monday, as the company’s shares surged by over 35% on the day on news of Adage Capital disclosing a nearly 19% passive stake in the biotech company.
Advaxis, Inc., currently valued at $145.65M, has a median Wall Street price target of $12.00 with a high target of $15.00. Approximately 2.20M shares have already changed hands, compared to the stock’s average daily volume of 200.60K.
In the past 52 weeks, shares of Princeton, New Jersey-based company have traded between a low of $2.46 and a high of $7.73 with the 50-day MA and 200-day MA located at $3.37 and $3.20 levels, respectively. Additionally, shares of ADXS have a Relative Strength Index (RSI) and MACD indicator of 92.49 and +1.65, respectively.
ADXS currently prints a one year return of about 33.57% and a year-to-date return of around 32.31%.
Advaxis, Inc recently traded at $7.41, up $1.83.
ChinaNet Online Holdings, Inc. (CNET) is higher by approximately 46% this session after the company announced that it has signed a long-term strategic partnership agreement with MediaFun Creative for cloud print services company based in Taiwan.
ChinaNet Online Holdings, currently valued at $33.63M, has a median Wall Street price target of $2.50. Approximately 4.88M shares have already changed hands, compared to the stock’s average daily volume of 2.84M.
In the past 52 weeks, shares of Beijing, China-based business-to-businesses Internet services company have traded between a low of $0.61 and a high of $4.06. The name currently prints a one year return of about 43.84% and a year-to-date return of around 25.00%.
ContraFect Corporation (CFRX) is a big mover this session, as its shares are up nearly 37%. The surge came after the biotechnology company announced that the U.S. Food and Drug Administration (FDA) completed the review of its submission and has removed the full clinical hold on ContraFect’s investigational new drug (IND) application for CF-301. This action allows for the initiation of clinical trials, which ContraFect expects to commence in Q1 2015.
Julia P. Gregory, ContraFect’s CEO commented, “CF-301 will be the first recombinant bacteriophage lysin allowed by FDA to advance to human clinical trials, marking a very important step for patients with serious infection.”
In today’s session, the equity is higher by nearly a point, changing hands at $3.75 a share.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply